UNITED THERAPEUTICS CORP

Drug pipeline (6)

Asset	Stage	Revenue	Trials	Status
TYVASO DPI	approved	$326.6MQ2 2026	7	approved
REMODULIN	approved	$126.3MQ2 2026	7	approved
TYVASO	approved	$126.0MQ2 2026	7	approved
ORENITRAM	approved	$125.7MQ2 2026	6	approved
UNITUXIN	approved	$65.2MQ2 2026	2	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (74)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00069511	phase2	unknown	2003-07-01	—	United Therapeutics	12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
NCT01172496	phase1	completed	2010-08-01	2010-08-01	United Therapeutics	A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
NCT01104870	phase2	completed	2010-04-01	2013-01-01	United Therapeutics	A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
NCT01934582	phase3	completed	2013-08-01	2013-11-01	United Therapeutics	A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
NCT03496623	phase3	terminated	2018-05-08	2022-10-13	United Therapeutics	A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

FDA applications (6)

Application

Approved

Type

Applicant

Products

NDA 214324

2022-05-23

NDA

UNITED THERAPEUTICS CORP

NDA 208276

2018-07-30

NDA

UNITED THERAPEUTICS CORP

BLA 125516

2015-03-10

BLA

UNITED THERAPEUTICS CORPORATION

NDA 203496

2013-12-20

NDA

UNITED THERAPEUTICS CORP

NDA 022387

2009-07-30

NDA

UNITED THERAPEUTICS CORP